Drug Trial Radar · NCT01710176
Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy
Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
550
Actual
Start
Jun 1, 2011
Primary completion
Jun 30, 2024
Study completion Jun 30, 2024
Sponsor
- Lead sponsor
- Italian Sarcoma GroupResearch network
- Sponsor type
- Research network
- Collaborators
- French Sarcoma Group; Grupo Espanol de Investigacion en Sarcomas
- First posted
- Oct 19, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized Phase III clinical trial in the setting of localized high-risk soft tissue sarcomas (STS). This study will compare a standard neoadjuvant chemotherapy with epirubicin plus ifosfamide versus a histology-driven chemotherapy, i.e. a chemotherapy tailored to the specific histology within the family of adult STS. Chemotherapy will be administered for 3 cycles. There will be five histological groups (representing 80% of STS), as follows: leiomyosarcoma, myxoid liposarcoma with hypercellularity (round cell MLPS), synovial sarcoma, malignant peripheral nerve sheath tumor (MPNST) and undifferentiated pleomorphic sarcoma. The histology-driven chemotherapy for these groups will be, respectively, gemcitabine plus dacarbazine, trabectedin, high-dose ifosfamide, ifosfamide plus etoposide, gemcitabine plus docetaxel. Other histological groups will also be included and registered, but treated only by standard chemotherapy. Patients who have already undergone definitive surgery will receive treatment post-operatively and patients needing a re-excision after inadequate surgery will be treated as patients in the two groups, but of course will not be evaluable for response. A centralized pathological review will be performed. Radiological response will be evaluated according to RECIST and to Choi criteria. Pathological response will also be recorded. The endpoint will be disease-free survival (DFS) and, secondarily, overall survival (OS) of patients receiving standard chemotherapy versus those receiving histotype-tailored chemotherapy. Additional aims will be to compare the probability of response of standard vs histotype-tailored chemotherapy and to determine the radiological and pathological response with standard chemotherapy vs tailored chemotherapy in each different histological group. Another aim will be to validate the response (both radiological and pathological) to preoperative chemotherapy as a surrogate endpoint for DFS and OS. Three hundred patients will be randomized over a 3-years period, from a pool of 400-450 registered patients. Translational research will be performed. Areas of research will include identification and validation of the potential predictive markers for each histological subgroups. The study is designed to verify the statistical hypothesis that histotype-tailored approach is associated, overall, with a 30% reduction in the hazard of relapse. However, in each different histological group, the effect of histotype-tailored chemotherapy, as compared to standard chemotherapy, can be different. To address this weakness an orthogonal study of response to chemotherapy as a surrogate of DFS and OS has been introduced into the trial. This study intends to extensively investigate the response (radiological and pathological) to preoperative chemotherapy and to validate it as a surrogate endpoint by showing that it correlates with disease free survival and overall survival.
Conditions
- Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults
Interventions
epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)Drug
gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)Drug
trabectedin 1.3 mg/m2Drug
high-dose ifosfamide 14 g/m2, given in in 14 daysDrug
etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)Drug
gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To compare the effect on disease-free survival of full-dose standard chemotherapy with histotype-tailored chemotherapy within the context of an integrated strategy for high risk soft tissue sarcomas typical of the adult.Time frame: 5 years
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Irccs Centro Di Riferimento Oncologico (Cro) -
Aviano (PN), Italy
Irccs Istituto Ortopedico Rizzoli (Ior) -
Bologna, Italy
Pres.Ospedal.Spedali Civili Brescia -
Brescia, Italy
Irst - Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori -
Meldola (FC), Italy
Irccs Istituto Europeo Di Oncologia (Ieo) -
Milan, Italy
Irccs Istituto Nazionale Dei Tumori (Int)
Milan, Italy
Irccs Istituto Nazionale Tumori Fondazione Pascale -
Naples, Italy
Irccs Istituto Oncologico Veneto (Iov)
Padova, Italy
Irccs Istituto Regina Elena (Ifo)
Roma, Italy
Irccs Istituto Clinico Humanitas -
Rozzano (MI), Italy
Presidio Sanitario Gradenigo Di Torino
Torino, Italy
Fondazione Del Piemonte Per L'Oncologia Ircc Di Candiolo -
Candiolo, TO, Italy
Hospital Vall D'Hebron
Barcelona, Spain
Hospital Clínico de Malaga
Málaga, Spain
Hospital Son Espases
Palma de Mallorca, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.